Background: Optimal follow-up (FU) strategy to detect potentially curable (PC) recurrences after treatment of localised clear cell renal cell carcinoma (ccRCC) is unclear. This study retrospectively analysed a large international database to determine recurrence patterns and overall survival (OS), as part of a wider project to issue recommendations on FU protocols. Objective: To analyse associations between RCC recurrences in patients with ccRCC, their risk group stratifications, treatments, and subsequent outcomes. Design, setting, and participants: Nonmetastatic ccRCC patients treated with curative intent between 1 January 2006 and 31 December 2011, with at least 4 yr of FU, were included. Patient, tumour and recurrence characteristics, Leibovich score, and management and survival data were recorded. Isolated local, solitary, and oligometastatic (three or fewer lesions at a single site) recurrences were considered PC, while all others were probably incurable (PI). Intervention: Primarily curative surgical treatment of ccRCC while at recurrence detection metastasectomy, systemic therapy, best supportive care, or observation. Outcome measurements and statistical analysis: Incidence, time to recurrence (TTR), and OS were measured. Competing risk analysis, Kaplan-Meier, and Cox regression models were used.
1.

Introduction
Contemporary studies show that among patients with localised clear cell renal cell carcinoma (ccRCC) treated with curative intent, radical nephrectomy, or partial nephrectomy, distant or local recurrences develop within 5 yr in 20-30% of cases [1] [2] [3] . Unfortunately, recurrences are often multifocal, and with the currently available systemic therapeutic options, complete disease eradication is unlikely. However, retrospective studies and a systematic review suggest that for some of these patients, complete local treatment of limited local or distant recurrence may result in prolonged overall survival (OS) and potential cure [4, 5] . Therefore, a rationale for follow-up (FU) is timely detection of potentially curable (PC) recurrences to subject them to metastasectomy or other forms of complete local treatment [6, 7] .
Several FU strategies based on clinicopathological characteristics (University of California, Los Angeles, Integrated Staging System; Leibovich score; and stage, size, grade, and necrosis score) are recommended for localised RCC in the major guidelines, all with comparable C-indexes for prediction of recurrence or survival [2, 3, [8] [9] [10] . However, the impact of FU on prolonging survival or cure was not assessed in the previous publications that had only the detection of recurrence as their main objective.
Given the poor evidence base demonstrated by a recent systematic review [11] , the current study was performed under the auspices of "the euRopEan association of urology renal cell carcinoma guidelines panel Collaborative multicenter consortium for the studies of follow-Up and recurrence patterns in Radically treated renal cell carcinoma patients" (RECUR). In contrast to previously published FU studies, we focused on further management after a recurrence was detected. We hypothesised that the outcome after treatment for recurrence may be dependent on risk score, symptoms at diagnosis of recurrence, age, and extent of the recurrence. For this purpose, recurrences were defined as potentially curable (PC) or probably incurable (PI) based on their extent. As a first step, the objective of the current study was to analyse associations between RCC recurrences in patients with ccRCC, their risk group stratifications, treatments, and subsequent outcomes.
2.
Patients and methods 
Definitions used for analyses
Patients with ccRCC were stratified into low, intermediate, and high risk of recurrence groups according to Leibovich score [2] . Patients with recurrences were subgrouped as symptomatic or asymptomatic at the time of detection, and also subgrouped based on whether recurrence detection was within or outside of the regular FU schedule. PC recurrences were defined as isolated local, solitary distant metastatic, or oligometastatic (three or fewer lesions at a single site). All other recurrences were valued as PI, that is, more than three lesions at a single site or dissemination to two or more sites. Although not formally recognised, PC and PI were bespoke definitions chosen through consensus by the RECUR consortium, were based on a clinical utility perspective, and have been used previously [12] .
Statistical analysis
A more detailed statistical analysis section is found in the Supplementary material, but in short, descriptive statistics were presented as categorical variables with percentages and continuous variables as median and IQR.
For continuous and nonparametric data, independent sample t test and 
group, the risk of having a recurrence that was PI was significantly higher (about 1.5 times) compared with a recurrence that was PC (HR 1.54, 95% confidence interval [CI] 1.08-2.21, p = 0.018). Considering all ccRCC patients with recurrences, 37.4% (n = 107) presented with symptoms and in total 29.7% (n = 85) detected outside the respective institutional FU protocols.
3.2.
Management of recurrences Figure 2 shows the distribution, curability, management, and survival outcomes of ccRCC patients developing recurrences. Figure 4B illustrates that the small group of PI recurrences among low-risk ccRCC patients (n = 22) had a higher disease-related mortality rate than higher PI risk score group patients, although this was not statistically significant. Of these 22 low-risk PI recurrences, 16 (72.2%) were symptomatic at recurrence and 14 (63.7%) were detected outside the regular FU-schedule. Patients with symptomatic recurrences had significantly shorter OS than asymptomatic recurrences (HR 2.84, 95% CI 2.10-3.86, p < 0.001), independent of being PC or PI ( Fig. 4C and D) .
3.4.
Competing risk analyses Figure 5A illustrates that ccRCC patients' cumulative incidence of death from other diseases exceeded the cumulative risk of recurrence in PC and PI groups at approximately 2 and 5 yr of FU, for low and intermediate risks, respectively. For high-risk patients, there was an early increase in cumulative incidence of recurrence for both PC and PI groups, which was more pronounced for PI patients. The competing cumulative risk of death from other diseases was much lower over time compared with both PC and PI recurrences in high-risk patients, of which the majority occurred within 2 yr. At approximately 2 yr of FU, the risk of death from ccRCC in the high risk score group was higher than the risk of death from other causes. Figure 5B demonstrates that for low-and intermediate-risk groups, patients >75 yr of age had a higher risk of death from other causes than the risk of death from ccRCC recurrence. For high-risk patients, death from ccRCC recurrence was higher than death from other causes, independent of age.
Discussion
Recurrence patterns in ccRCC are complex, and owing to a lack of comparative studies, optimal strategies for FU have 
not been established [7, 13, 14] . The current RECUR study showed 5-yr estimated RRs for ccRCC in line with earlier reports [2, 15, 16] . We found PC recurrences in almost half (45.8%) of the ccRCC patients with recurrence, in keeping with previous publications [9, [17] [18] [19] . In turn, approximately half of the PC patients received local treatment with curative intent of whom only 26 patients, that is, 19.8% of all patients with PC recurrences, were alive and had NED within the reported FU period. Results were not biased by excluding patients with <4 yr for FU. The TTR did not differ between PC and PI patients in the low-risk category. This, together with a low 5-yr RR, implies that for these patients less frequent FU imaging may be considered without increasing the risk of missing a recurrence. In addition, OS after recurrence for this cohort was in line with previous publications [12, 20, 21] . As expected, shorter survival time was observed in the PI group, and symptomatic recurrences were significantly correlated with poorer survival. Interestingly, low-risk patients in the PI group showed a nonsignificant trend towards worse OS compared with high-risk patients. While perhaps underpowered, it is intriguing that 72.7% low-risk patients had symptoms that led to the detection of recurrence. Although this may reflect a more aggressive tumour type, this poor outcome in the low-risk group may be a consequence of very low imaging frequencies.
Competing risk analysis for all ccRCC patients revealed several differences between risk groups. For low-risk ccRCC, the analysis suggests that, together with a low cumulative RR, patients may not need frequent FU within the first 2 yr. In addition, the cumulative risk of death from other causes starts to exceed that of RR for PC and PI around the same time point. At 5 yr, there seems to be an increase in RR for both PC and PI groups, suggesting, as proposed previously, a need for continued FU after this period [11] . However, the low overall RR in low-risk patients would require a high number needed to image to identify those with symptomatic recurrences when they might still be asymptomatic, and opens up to the discussion whether general practitioner-based FU strategies may lead to comparable disease-free survival and OS as well as symptom control instead of protocols involving risk-adapted repeat imaging. Furthermore, our results suggest that FU may not be necessary for low-risk patients aged >76 yr, in line with a recent publication analysing the impact of age and comorbidity on FU [22] . For intermediate-risk patients, the RRs for PC and PI Alive, free of disease, n = 2 (1.3% of PI) Alive, with disease, n = 5 (3.2% of PI) Dead of disease, n = 2 (1.3% of PI)
ObservaƟon n = 22 Fig. 2 -Flow chart of recurrence, curability, management, and survival outcome in 1265 patients with ccRCC. Reasons for withholding therapy from potentially curable (PC) patients and type of treatment given to patients deemed as probably incurable (PI) are provided. Palliative treatment was defined as systemic therapy or best supportive care, while observation refers to refraining from active palliative treatment due to no rapid progression of disease. ccRCC = clear cell renal cell carcinoma; RCC = renal cell carcinoma.
seem to run parallel to the risk of death from other causes until approximately 5 yr. After 5 yr, the cumulative incidence of death from other causes exceeds the RRs, suggesting the need for age-and/or performance status-dependent FU strategy from 5 yr onwards. For the high-risk group with most recurrences, the competing risk analysis showed that death from other causes had a lower incidence than that in low-and intermediate-risk groups, reflecting the high risk of death from ccRCC in this group. Finally, as observed previously, most recurrences in high-risk patients developed within 2 yr after initial surgery [3, [15] [16] [17] 19, 20, 23, 24] . Perhaps the most intriguing observation from the RECUR analysis is that FU may not have a major impact on curing recurrent ccRCC. While this is not surprising in patients with multiple recurrences, it is unexpected in patients with PC solitary or oligometastatic recurrence.
Moreover, for patients with PI recurrences, observation was the management in 25% because the extent of metastasis did not justify the start of systemic therapy, further questioning the need for intensive FU. Potentially more intensive FU among these patients (PI) may have resulted in earlier detection of recurrences and access to local treatments. However, the very early onset of recurrences in high risk patients suggests that more intensified imaging does not necessary result in better survival. Early identification of PC recurrences is a major objective of FU. However, the results of RECUR indicate that disease-free survival despite local treatment is largely unattainable in patients with recurrence from high-risk tumours (2%). At the other end of the risk spectrum, cure may be achieved in low-risk recurrences, but the low RR counters an intensive imaging FU strategy. Before recommending 
EUF-461; No. of Pages 10 any alteration to the FU strategy for ccRCC to identify curable recurrences early, one must consider that only 53% of PC recurrences were managed with local therapy, mainly metastasectomy. While this may in part be a consequence of a retrospectively assigned definition of potential resectability, this reflects real-world management, with comorbidities, poor performance, or rapid disease development arguing against local management of metastases. Finally, a further consideration for optimising FU is the timely identification of patients with multiple recurrences who would benefit from systemic therapy. However, current systemic therapies do not cure, and placebo-controlled studies in metastatic RCC have demonstrated no inferior survival if patients crossed over into the active arm after further disease progression [25] .
The strengths of this study are the large cohort and robust time-to-event analysis by excluding patients with <4 yr of FU. In addition, by excluding patients who died within 90 d after surgery, we reduced potential confounding of misinterpreting primary metastatic disease as early recurrence and postoperative complications as early death. However, this study has several limitations mainly due to its retrospective nature. First, approximately 12% of patients were excluded from analysis because of a lack of essential data. Furthermore, our study did not collect data on comorbidities, that is, performance status. Patients with good performance status may have had more aggressive treatment for any recurrence, while those with poor performance status did not, thus influencing the RR and survival outcome. For planned prospective RECUR database, we therefore intend to collect these data at the time of both primary surgery and recurrence detection. In addition, the definitions of PC (solitary metastasis, oligometastasis with three or fewer metastases at a single site, or local recurrence) and PI (more than three metastases at a single site or disseminated disease) were based on previously published studies on local treatment and survival outcome being dependent on the number of metastases and metastatic sites [4, 5] , and were established by experts within the European Association of Urology Guidelines Panel for RCC. Although the definition takes the perspective of management intention at the time of diagnosis of the recurrence into consideration and has previously been published in a peer-reviewed journal [12] , we acknowledge that it is not universally accepted. Finally, incidence and pattern of recurrence may have been influenced by the frequency and accuracy of imaging, which differed in the FU protocols between collaborating institutions. However, these differences are a strength of the RECUR database, which, with growing data collection, may reveal the weaknesses of certain FU strategies. While the currently collected data on frequency and type of imaging in the subgroup of patients with ccRCC recurrence (n = 286) would result in subgroups of inferior size, the future intent of the authors is to perform an in-depth analysis of these factors in a meaningful study population.
Conclusions
To assess the true impact of FU on survival, comprehensive data regarding the management of recurrence and its subsequent outcomes are essential; the RECUR database provides such data for ccRCC. In the low-risk group, recurrences were rare but predominantly symptomatic, which was an indicator of poorer survival outcome. Overall longterm disease-free survival following treatment of recurrences with curative intent is disappointing. This is most prominent in the Leibovich high-risk group, which harbours most patients with PC recurrences. Competing risk analysis suggests an age-and risk score-dependent approach to FU protocols, the specifics of which need further investigation. Whether regular FU pre-empts symptomatic recurrences is unproved. This and varied FU strategies need to be studied in prospective clinical trials.
